Loading clinical trials...
Loading clinical trials...
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
Conditions
Interventions
Infusion of NEXI-001 T Cells
Locations
5
United States
City of Hope Comprehensive Cancer Center
Duarte, California, United States
Advent Health Medical Group Blood & Marrow Transplant
Orlando, Florida, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York, United States
The James Cancer Hospital and Solove Research Institute OSUCC
Columbus, Ohio, United States
Start Date
February 20, 2020
Primary Completion Date
October 1, 2024
Completion Date
March 1, 2025
Last Updated
January 16, 2024
NCT03520647
NCT07451912
NCT06660368
NCT05143996
NCT05534620
NCT02143830
Lead Sponsor
NexImmune Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions